Apply to Trial

Compensation: Varies

Number of Visits: Unknown

Duration: 48 weeks

LY3549492 for Obesity

Not currently recruiting at 54 trial locations

Overseen ByJeffrey A Norton

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Eli Lilly and Company

Disqualifiers: Diabetes, Pancreatitis, Renal impairment, others

Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called LY3549492, an experimental drug, to assess its effects on adults with obesity or those who are overweight. Researchers aim to determine how different doses of LY3549492 compare to a placebo, which contains no active medicine. Eligible participants should have a BMI of 30 or higher, or a BMI between 27 and 30 with a weight-related health issue, and must have maintained a stable weight for the past three months. The study will last about a year, with participants taking the treatment orally. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that LY3549492 is likely to be safe for humans?

Research shows that LY3549492 is being tested for safety and tolerability in both healthy individuals and those with obesity. In studies with healthy participants, researchers have assessed how well the treatment is tolerated and monitored for any adverse effects. So far, no serious safety issues have been reported.

This trial is in Phase 2, indicating that the treatment has already demonstrated some safety in earlier trials. While detailed information on side effects from this phase is not yet available, the treatment's progression to this stage suggests it was well-tolerated in previous studies. Participants in this trial will receive different doses of LY3549492 to evaluate its safety at various levels.¹ ² ³ ⁴ ⁵

Why do researchers think this study treatment might be promising for obesity?

Researchers are excited about LY3549492 for obesity because it offers a potentially new mechanism of action compared to existing treatments like orlistat, phentermine, and liraglutide. While current options often focus on reducing appetite or fat absorption, LY3549492 is believed to act differently, although its exact mechanism is still under investigation. This drug is administered orally, which could provide a simpler and more convenient option for patients. The prospect of a novel approach to tackling obesity is what makes LY3549492 a promising candidate in the field of weight management.

What evidence suggests that LY3549492 might be an effective treatment for obesity?

Research has shown that LY3549492 might aid weight loss in individuals with obesity. Studies in adults with type 2 diabetes found that LY3549492 affects blood sugar management, which might also influence weight. Although specific data on obesity is still being collected, the drug's effects on metabolism appear promising. Early results from other studies suggest that LY3549492 could assist with weight management by altering energy use in the body. Participants in this trial will receive varying doses of LY3549492 or a placebo to further assess its potential benefits for weight management.¹ ² ³ ⁴ ⁵

Who Is on the Research Team?

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This clinical trial is for adults who are overweight or have obesity. Participants will be involved in the study for about one year to assess the effectiveness of a new medication, LY3549492.

Inclusion Criteria

I was assigned male at birth.

W8M-MC-CWMM: Have a BMI ≥27 kilograms per square meter (kg/m²)

My weight has been stable, with less than 5% change, for the last 3 months.

See 1 more

Exclusion Criteria

W8M-MC-GN01: Individuals who are of childbearing potential

W8M-MC-CWMM: Have a lifetime history of suicide attempts

I have had symptoms of gallbladder disease in the last 2 years.

See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3549492 or placebo orally for weight management

48 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

LY3549492

Trial Overview The trial is testing LY3549492 against a placebo to see if it helps with weight management. A placebo is an inactive substance that looks like the drug but has no treatment value.

How Is the Trial Designed?

6Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3549492 Dose 5Experimental Treatment1 Intervention